Founded with a mission to advance pharmaceutical research and metabolic analysis, Aconabolics specializes in the synthesis of stable, isotopically labeled organic acids, ketoacids, and amino acids. Their proprietary reaction pathways facilitate the production of both known and non-fermentable metabolites, catering to diagnostics in pharmaceutical research and metabolic analysis. The company's major products include isotopic and structural isomers of biochemical intermediates and analogs, focusing on early detection technologies for conditions like cancer and bacterial infections.

Aconabolics has garnered attention for its innovative contributions to the field of diagnostics and pharmaceutical research. While specific notable affiliated people and investors are not detailed, the company's impact is evident in its role in enhancing early detection methods for critical health conditions. By providing high-quality, specialized biochemical intermediates, Aconabolics supports advancements in medical research, potentially improving patient outcomes and contributing to the broader scientific community.